Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
NCT ID: NCT00050310
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2002-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The following individuals may be eligible for this study:
1. People with confirmed or suspected anthrax (inhalational, cutaneous or gastrointestinal, either acute or recovering);
2. People exposed to anthrax who have no clinical symptoms.
3. Healthy people who have not been exposed to anthrax and have been vaccinated with AVA.
Those enrolled in the study will undergo the following tests and procedures.
Infected and exposed individuals:
* Symptomatic participants will have the following clinical procedures if medically necessary:
* a) blood tests for cell counts, chemistries and evidence of anthrax bacteria;
* b) nasal swab to test for evidence of anthrax
* c) chest X-ray;
* d) computed tomography (CT) scan (special X-rays to examine the lungs or abdomen);
* e) echocardiogram to examine the heart
* f) magnetic resonance imaging (MRI), a special imaging test using a magnetic field and radio waves to examine the infected area of skin and soft tissue for patients with cutaneous anthrax.
* All subjects (with or without symptoms) will have the following research procedures:
* a) blood tests to examine immune response to anthrax;
* b) throat swab to test for evidence of anthrax
* c) nasopharyngeal wash to test for anthrax. Water is sprayed into the nostrils and then allowed to drain for collection in a cup;
* d) induced sputum to test for presence of and immune response to anthrax. A mask with a saline mist is placed over the subject s mouth and nose, causing the subject to cough and produce sputum from the lungs. The sputum is collected in a cup this is for individuals 18 and older who do not undergo bronchoscopy, described below.
* Participants 18 years of age and older may have the following optional research procedures:
* a) leukapheresis or plasmapheresis (see description under non-infected, vaccinated individuals above);
* b) lymph node biopsy. A sample of lymph node tissue is surgically removed under local anesthetic;
* c) bronchoalveolar lavage. This 15- to 30-minute procedure is done in the intensive care unit. The mouth, nasal passages, throat and airways are numbed with lidocaine and a thin flexible tube is passed through the nose into the lung airways. Samples of cells and secretions are obtained by rinsing (lavage) the airways with salt water. The fluid is analyzed for infection, inflammatory cells and inflammatory chemicals.
All infected and exposed individuals will have periodic medical history and physical exam evaluations and be offered treatment or prophylaxis (treatment to prevent infection) with antibiotics, according to the guidelines of the Centers for Disease Control and Prevention (CDC). Patients will be monitored for at least 24 months after antibiotic treatment, or longer if circumstances warrant.
Non-infected, vaccinated individuals
1. medical history and physical examination
2. blood tests-- between 10 and 50 ml (2-10 teaspoons) of blood will be drawn at a time, and not more than 450 ml will be taken in a 6-week period. Based on the blood test results, other optional research procedures may be requested
3. leukapheresis to collect white blood cells and plasmapheresis to collect plasma (the liquid part of the blood). For both of these procedures, blood is collected through a needle placed in an arm vein. The blood flows into a special machine that separates it into its components by spinning. The desired components (white cells or plasma) are removed and the rest of the blood is returned to the body through the same needle or a second needle in the other arm.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute Infection (confirmed or suspected)
adults and children with acute anthrax infection
No interventions assigned to this group
AVA Recipient/Healthy Volunteer
healthy adults who have received AVA vaccine
No interventions assigned to this group
Recovered
adults and children in recovering phase of anthrax infection
No interventions assigned to this group
Suspected Exposure
adults and children with suspected exposure to anthrax
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Although the study is open to participants at least 3 years old, pediatric anthrax cases are historically rare and essentially of the cutaneous type. Therefore, few, if any pediatric subjects are expected.
Decisionally impaired subjects will be included in this study only if a Legally Authorized Representative (LAR) understands and is willing to sign a written informed consent document.
1. Inhalation Anthrax (acute or recovering infection)
CONFIRMED:
--nonspecific febrile illness followed by sepsis and/or respiratory failure
AND
--B anthracis isolation (via culture) from any site OR 2 supportive lab tests
OR SUSPECTED:
--nonspecific febrile illness followed by sepsis and/or respiratory failure with no alternative diagnosis
AND
--one supportive lab test OR direct epidemiological link to a confirmed environmental exposure
2. Cutaneous Anthrax (acute or recovering infection)
CONFIRMED:
--characteristic lesion (papule-\>vesicular-\>depressed black eschar plus or minus edema, erythema, necrosis, or ulceration)
AND
--B anthracis isolation (culture) from any site OR 2 supportive lab tests
SUSPECTED:
--Characteristic lesion with no alternative diagnosis
AND
--one supportive lab test OR direct epidemiological link to a confirmed environmental exposure
3. Gastrointestinal Anthrax (acute or recovering infection)
CONFIRMED:
--Severe abdominal pain often associated with bloody vomiting/diarrhea followed by fever/septicemia
AND
--B anthracis isolation (culture) from any site OR 2 supportive lab tests
SUSPECTED:
--Severe abdominal pain often associated with bloody vomiting/diarrhea followed by fever/septicemia with no alternative diagnosis
AND
--1 supportive lab test OR direct epidemiological link to a confirmed environmental exposure
These definitions were subsequently updated by the CDC in 2010 to accept clinically compatible symptoms plus one of the following: a positive culture, a positive immunohistochemical stain for antigen, a 4-fold increase in anti-PA IgG or a positive documented exposure with detection of DNA via PCR (26).
4. Exposed individuals who are clinically asymptomatic.
5. Past or imminent vaccination in healthy (non-anthrax exposed).
6. Hemodynamically and clinically stable at time of evaluation at NIH.
* Hemodynamically: stable vital signs
* Clinically: no obvious signs of disease progression (e.g. worsening pleural effusions or increasing cutaneous edema)
* acute/newly recovered patients must be receiving standard antimicrobial therapy
7. Participant agrees to stored samples.
Exclusion Criteria
3 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary E Wright, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
NIH Clinical Center Office of Patient Recruitment (OPR)
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Dalton R. Genetic sleuths rush to identify anthrax strains in mail attacks. Nature. 2001 Oct 18;413(6857):657-8. doi: 10.1038/35099687. No abstract available.
Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA. Inhalational anthrax: epidemiology, diagnosis, and management. Chest. 1999 Nov;116(5):1369-76. doi: 10.1378/chest.116.5.1369.
Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep. 2001 Nov 9;50(44):973-6.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
020110
Identifier Type: -
Identifier Source: org_study_id
02-I-0110
Identifier Type: -
Identifier Source: secondary_id